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Abstract Mutations in SLC25A22 are known to cause neo-
natal epileptic encephalopathy and migrating partial seizures
in infancy. Using whole exome sequencing we identified four
novel SLC25A22 mutations in six children from three fami-
lies. Five patients presented clinical features similar to those in
the literature including hypotonia, refractory neonatal-onset
seizures and developmental delay. However, the sixth patients
presented atypically with isolated developmental delay, devel-
oping late-onset (absence) seizures only at 7 years of age.
Abnormal metabolite levels have not been documented in
the nine patients described previously. One patient in our se-
ries was referred to the metabolic clinic because of persistent
hyperprolinaemia and another three had raised plasma proline
when tested. Analysis of the post-prandial plasma amino acid
response in one patient showed abnormally high concentra-
tions of several amino acids. This suggested that, in the fed
state, when amino acids are the preferred fuel for the liver,
trans-deamination of amino acids requires transportation of
glutamate into liver mitochondria by SLC25A22 for deami-
nation by glutamate dehydrogenase; SLC25A22 is an impor-
tant mitochondrial glutamate transporter in liver as well as in
brain. Electronmicroscopy of patient fibroblasts demonstrated
widespread vacuolation containing neutral and phospho-lipids
as demonstrated by Oil Red O and Sudan Black tinctorial
staining; this might be explained by impaired activity of the
proline/pyrroline-5-carboxylate (P5C) shuttle if SLC25A22
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transports pyrroline-5-carboxylate/glutamate-γ-semialdehyde
as well as glutamate.
Abbreviations
GSA Glutamate-γ-semialdehyde
EEG Electroencephalogram
HP2 Hyperprolinaemia type II
LAMP2 Lysosome-associated membrane protein 2
LSD Lysosomal storage disease
MRI Magnetic resonance imaging
NAD+ Nicotinamide adenine dinucleotide
(oxidised form)
NADPH Nicotinamide adenine dinucleotide phosphate
(reduced form)
P5C Pyrroline-5-carboxylate
p62 Nucleoporin 62
PLP Pyridoxal 5’-phosphate
PND Prenatal diagnosis
SLC25A22 Solute carrier family 25 (mitochondrial carrier:
glutamate) member 22
VEP Visual evoked potential
WES Whole exome sequencing
Introduction
SLC25A22 deficiency causes neonatal epileptic encephalop-
athy and migrating partial seizures in infancy. In nine patients
(Molinari et al 2005; Molinari et al 2009; Poduri et al 2013;
Cohen et al 2014), no abnormalities of routine metabolic in-
vestigations were reported. Patients presented with refractory
seizures, hypotonia, visual inattention with evidence of post-
retinal dysfunction, microcephaly, a burst-suppression pattern
on EEG and hypoplasia of the cerebellum and corpus
callosum on MRI.
SLC25A22 is a mitochondrial glutamate transporter
(Fiermonte et al 2002). In liposomes it catalyses glutamate
exchange (bidirectional transport) and uniport (Fiermonte
et al 2002). Digitonin-permeabilised fibroblasts from patients
with SLC25A22 mutations show reduced oxidation of gluta-
mate (Molinari et al 2005). Given the widespread expression
of SLC25A22, it is surprising that no amino acid abnormalities
were reported. We present six patients with novel
homozygous/compound heterozygous mutations in
SLC25A22 . The f i r s t was r e f e r r ed becau se o f
hyperprolinaemia; for three others, first-line biochemical
screening showed hyperprolinaemia. All three patients tested
showed lipid vacuoles in fibroblasts.
Materials and methods
This study was approved by the National Research Ethics
Service Committee, Bloomsbury (13/LO/0168).
Chemical reagents
Cell culture reagents were from Life Technologies (Paisley, UK);
other chemicals were from Sigma Aldrich (Gillingham, UK).
Genetic analysis
Whole exome sequencing (WES) of DNA from blood was
performed for patients 1 and 4–6 (BGI Genomics, Hong
Kong). DNA, captured using the Agilent SureSelect v4
(51 Mb) kit (Santa Clara, CA), was sequenced on an
Illumina HiSeq 2000 platform (San Diego, CA). Data was
aligned to the human_g1k_v37 genome and analysed using
Ingenuity Variant Analysis software (Redwood City, CA)
(Reid et al 2015). Prioritisation of variants was based on:
candidate genes for phenotype, predicted effect on gene func-
tion, conservation of amino acid position and frequency of the
variant in the databases including the 1000 genomes, Ensembl
and the Human Gene Mutation Database*. SIFT* and
PolyPhen-2* were used to predict pathogenicity. Sanger se-
quencing was used to confirm SLC25A22 mutations and for
prenatal diagnoses (PND). SLC25A22 sequences from differ-
ent species (accession numbers in Supplementary Methods)
were aligned using ClustalW2* (Thompson et al 1994). The
human reference sequence used was NM_024698.5)
*URLs follow References
Fibroblast culture and tinctorial staining
Fibroblasts were grown in Ham’s F10 medium containing
10% fetal bovine serum, penicillin (100 U/L) and streptomy-
cin (100 μg/mL) at 37 °C in 5% carbon dioxide. Once 80%
confluent, fibroblasts were detached using 0.25% trypsin-
EDTA, resuspended in Ham’s F10 medium and approximate-
ly 8x106 cells were immobilised as a monolayer on glass
slides using a Cytospin 4 (Thermo Scientific). Cells were
allowed to air-dry, stained using H&E, Sudan Black, Oil
Red O and Luxol Fast Blue (Suvarna et al 2012) and
visualised using a Nikon Optiphot microscope; images were
captured using a Leica DMD108.
Nucleoporin (p62) immunofluorescence
and quantification
Nucleoporin (p62) immunofluorescence was performed as in
Yasin et al (2013) and CellProfiler 2.1.1 (Carpenter et al 2006)
was used to analyse the images obtained (Supplementary
Methods).
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Electron microscopy (EM)
EM was undertaken essentially as in Yasin et al (2013)
(Supplementary Methods).
Results
Case studies
Patients 1–3
A 2y old boy (patient 1) presented to the metabolic clinic with
epilepsy, severe developmental delay and hyperprolinaemia.
His parents are first cousins of Afghan origin. From birth he
had central and peripheral hypotonia and delayed feeding. At
6 wks he developed myoclonic and tonic-clonic seizures, dys-
tonic movements and was not fixing and following. At 2y he
showed severe global developmental delay, visually unre-
sponsive behaviour with impaired cortical responses to light
and myoclonic and generalised tonic-clonic seizures. MRI
showed frontotemporal hypoplasia, globally delayed
myelination, delayed temporal pole myelination, prominent
cerebellar folia and a small splenium. Extensive investigations
were undertaken (Supplementary Tables 1–4, 6). Amino acid
profiles were consistently abnormal in plasma, urine and CSF.
Plasma proline was 322–1195 μmol/L (n = 11; ref: 85–
290 μmol/L). At 2 y 8 mo, plasma amino acids were assayed
after a 6 hr fast and 1 hr, 2 hr and 4 hr post-prandially
(Supplementary Table 2). A muscle biopsy showed increased
lipid and glycogen but no ragged-red or cytochrome oxidase-
negative fibres, and normal activities of respiratory chain
complexes. Ammonia was slightly raised once (50; ref:
<40 μmol/L) and white cell ubiquinone was low (24; ref:
37–133 pmol/mg). At 7 y, seizures were well controlled on
levetiracetam (40 mg/kg/day), sodium valproate (20 mg/kg/
day) and pyridoxine (15 mg bd). At 7 y 11 mo, he was
wheelchair-bound and severely developmentally delayed, al-
though continuing to make slow progress. Eye movements
were full but he was not fixing or following. He had no dys-
tonic movements, and reflexes were elicitable in his upper
limbs only.
In the mother’s next pregnancy, PND revealed the homo-
zygous SLC25A22 mutation and the parents elected to termi-
nate. The following pregnancy was a twin pregnancy and
PND indicated that both fetuses (patients 2 and 3) had homo-
zygous SLC25A22 mutations; this time the parents opted not
to terminate. As their affected brother had a low white cell
ubiquinone, the twins were commenced on ubiquinone
(10 mg/kg/day) from birth. Initially they appeared less severe-
ly affected than their brother. Whereas at 6 wks patient 1 was
profoundly hypotonic, visually inattentive and had seizures
and dystonic movements, at 6 wks the twins had milder, and
mainly axial, hypotonia. They were both smiling and fixing
and had no abnormal movements. Both had a smooth philtrum
and low set ears. At 16 wks, both twins developed seizures
with a flexor spasm-like semiology and multifocal EEG ab-
normalities; levetiracetam (40 mg/kg/day) was started. At 12
mo, both twins have generalised tonic-clonic seizures twice a
week and have developmental stasis. Patient 2 occasionally
fixes and smiles and patient 3 occasionally fixes but does not
smile. They are hypotonic with no head control but normal
reflexes. Plasma amino acids were measured on two occasions
and at 11 mo patient 2 showed a proline of 418 μmol/L (ref:
85–290 μmol/L), alongside other mild abnormalities
(Supplementary Table 2). Other plasma proline results for
patients 2 and 3 were within the normal range.
Patients 4 and 5
Patient 4, a 6 y old girl, presented with epilepsy and severe
developmental delay. Her parents are first cousins of Syrian
origin. She has a healthy older brother and an affected younger
sister. Within the first month of life she developed a febrile
illness followed by seizures, treated with sodium valproate
with some clinical improvement. Her current treatment is so-
dium valproate 30 mg/kg/day and clonazepam 500 μg nocte.
She continues to have brief (<1 min) seizures at least week-
ly—usually tonic seizures and sometimes in clusters. She
started crawling and sitting independently at 2 y 6 mo. At 7
y she could babble but had no words. Developmental progress
was very slow but she had not regressed. She was globally
hypotonic although lower limb reflexes were brisk. At 6 y, an
EEG showed symmetrical diffuse irregular slow wave activity
and MRI showed symmetrical signal abnormalities of the in-
sular cortex and adjacent capsular white matter, delayed tem-
poral pole myelination, prominent cerebellar folia and a small
splenium. Plasma proline was consistently > 350 μmol/L
(n = 2; ref: 85–290 μmol/L).
Patient 5, the younger sister of patient 4, attended our clinic
alongside her sister. She was clearly more mildly affected. She
presented at 3 y 6mowith developmental delay; she had never
had any seizures. She started walking at 3 y, and 6 months
later could take ten steps and had ten words. Although better
than her sister, she is significantly delayed. She has never
suffered regression. She was hypotonic with normal reflexes,
joint laxity, very flat feet and a broad-based gait. She had
hypermetropia, astigmatism and a right convergent squint.
She is microcephalic and MRI at 2 y demonstrated delayed
temporal pole myelination, prominent cerebellar folia and a
small splenium. Absence seizures were detected at 7y.
Investigations showed a mildly elevated ammonia in pa-
tient 4 (56; ref: < 40 μmol/L) and some amino acid abnormal-
ities (see below). Patient 4 had amuscle biopsy, which showed
increased lipid, increased fibre size variation (scattered small
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fibres) and mild myopathic features. Respiratory chain com-
plexes were normal.
Patient 6
Patient 6 presented at 1 mo with prolonged jaundice and de-
layed feeding. Investigations were unremarkable and the jaun-
dice resolved. At 6 wks, she developed focal seizures and
asymmetric clonic episodes and an ictal EEG showed a right
parietal lobe origin. The semiology subsequently changed
with clusters of infantile spasms and multifocal discharges
without hypsarrhythmia. The interictal EEG then deteriorated
to a semi-discontinuous pattern with high amplitude multifo-
cal discharges. Seizures were resistant to phenobarbitone,
vigabatrin, prednisolone, carbamazepine, levetiracetam and
pyridoxal 5’-phosphate. At 10 mo, she is developmentally
impaired with hypotonia, poor head control, delayed feeding
and extremely delayed visual development. She has no visual
fixation, smiling, cooing or motor control, although she feeds
orally without choking. MRI was normal.
Amino acid abnormalities
The index patients (patients 1, 4 and 6) had elevated plasma
proline on all occasions tested (n = 11, 2 and 2 respectively)
and proline was elevated in a recent sample from patient 2
(Supplementary Table 2). Glutamate was elevated in >50%
of the samples from each patient. However, patients 3 and 5
had normal plasma proline. In patient 1, amino acids were
assayed after a 6-hour fast and then post-prandially. Only pro-
line was elevated in the fasting sample, but in post-prandial
samples, several amino acids were elevated: leucine, isoleu-
cine, valine, alanine, tyrosine, lysine and arginine. Random
samples from patient 4 showed variable elevations of isoleu-
cine, valine, alanine, lysine and arginine. Plasma amino acids
from patients 2, 3 and 6 showed mild elevations of some of
these amino acids plus glutamate and ornithine. A random
plasma sample from patient 5 was normal. It should be
stressed that most of the plasma samples were taken in a rou-
tine clinic setting and so values for glutamine and glutamate
should be treated with some caution (spontaneous hydrolysis)
as should values of arginine and ornithine (red cell arginase
activity).
Urinary amino acid analysis showed raised glutamate in
patients 1 and 5 and raised proline in patients 1, 5 and 6
(Supplementary Table 3). Patient 1 also had elevated CSF
proline and patients 1 and 5 had a low CSF glutamate
(Supplementary Table 4).
Fibroblast vacuolation
EM of fibroblasts from three patients showed extensive vacu-
olation with empty, single membrane-bound vacuoles in all.
Tinctorial stains showed punctate staining using Oil Red O
and Sudan Black indicating neutral lipids and phospholipids,
respectively. Luxol Fast Blue staining for sphingomyelin was
negative. Acid phosphatase and LAMP2 immunostaining was
comparable to controls indicating no evidence of lysosomal
dysfunction. Immunofluorescence of p62 in patient fibroblasts
demonstrated an increase in number and size of
autophagosomes compared to controls (Fig. 1), however, a
statistically significant increase was only seen in one patient
(Fig. 1W).
Whole exome sequencing (WES)
SLC25A22 sequence changes were identified in four cases by
WES and in two by prenatal Sanger sequencing. Patients 1–3
are homozygous for c.166A>C; p.Thr56Pro, patients 4 and 5
are homozygous for c.886G>A; p.Ala296Thr and patient 6 is
compound heterozygous for c.235G>A; p.Glu79Lys and
c.746T>A; p.Val249Glu. All mutations were predicted ‘dam-
aging’ by SIFT and all, with the exception of p.Val249Glu
(predicted ‘possibly damaging’), were predicted ‘probably
damaging’ by PolyPhen-2. None had been reported in
Ensembl, 1000 Genomes or Exome Variant Server databases.
A restriction enzyme digest test confirmed segregation of the
p.Thr56Pro mutation. Sanger sequencing confirmed segrega-
tion of p.Ala296Thr, and confirmed maternal inheritance of
p.Glu79Lys and paternal inheritance of p.Val249Glu. No po-
tentially pathogenic changes were identified in genes known
to cause hyperprolinaemia (PRODH and ALDH4A1).
In light of the EM findings, WES data was scrutinised for
variants in lysosomal storage disorder (LSD) genes. In one of
the families, a homozygous variant (c.340G>A; p.Val114Met)
was identified in SMPD1 (Niemann-Pick disease type A/B;
reference sequence NM_000543.4). This variant has a minor
allele frequency of < 0.01 (1000 Genomes) and is predicted
‘tolerated’ and ‘benign’ by SIFT and PolyPhen-2, respective-
ly. Leucocyte sphingomyelinase activity was 0.43 nmol/hr/mg
protein (ref: 0.86–2.8) — lower than in heterozygotes (0.7–
1.3), but higher than in affected homozygotes (0.08–0.18),
indicating that this variant is probably not pathogenic.
Discussion
WES identified four novel mutations in SLC25A22 in six chil-
dren from three families. They affect highly conserved regions
of SLC25A22 (Supplementary Fig. 1), one of two mitochon-
drial glutamate transporters; SLC25A18 encodes the
paralogous glutamate transporter sharing 63% sequence iden-
tity with SLC25A22. All mutated amino acids, except Val249,
are also conserved in SLC25A18; all mutations are predicted
damaging. Both SLC25A18 and SLC25A22 are ubiquitously
expressed, with SLC25A22 present in higher amounts in all
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tissues except brain. SLC25A22 has a higher Km and Vmax
than SLC25A18 with respect to glutamate (Fiermonte et al
2002), suggesting that SLC25A22 may become active to cope
with higher cytosolic concentrations of glutamate. We consid-
ered the possibility that polymorphisms in SLC25A18 might
be responsible for the variation of the clinical and biochemical
features between siblings (patients 1–3 and 4&5 respectively),
however, no polymorphisms in SLC25A18 were found in the
exome sequencing data of any of these patients.
Despite harbouring novel mutations, patients 1, 2, 3, 4 and
6 presented like previous patients with marked hypotonia,
onset of refractory seizures within the first 3 months of life,
and developmental delay (Table 1, Supplementary Table 1).
Patient 5, however, presented at 3 y 6 mo with developmental
delay and only developed seizures at 7 y. MRI scans after age
2 y all showed a small splenium, prominent cerebellar folia
and delayed temporal pole myelination as well as a small optic
chiasma (consistent with post-retinal dysfunction) (Fig. 2).
Fig. 1 Structural and ultrastructural examinations of SLC25A22-
deficient fibroblasts. Fibroblast cell culture from control (a, e, i, m, q),
patient 1 (b, f, j, n, r), patient 4 (c, g, k, o, s) and patient 5 (d, h, l, p, t).
Ultrastructural examination by electron microscopy revealed widespread,
almost exclusively empty vacuoles in all patients (a-h). Patients showed
excess accumulation of lipid (i-l, Oil Red O; m-p, Sudan Black).
Immunofluorescence of the autophagy marker p62 revealed increases in
number and area of p62 punctae in patient cells, indicating a possible
increase in autophagy or mitophagy due to mitochondrial dysfunction.
Four representative images of p62 immunofluorescence per case were
analysed using CellProfiler 2.1.1. All patient cells showed an increase
in the mean number of p62 punctae per cell, which was significant in
patient 4 (p = 0.002) (q). The mean area of p62 punctae in patient 1 was
also increased compared to controls (r). Taken together, the mean total
area of p62 staining per cell is increased in all patients compared to
controls and significantly in patient 4 (p = 0.002) (s). Scale bars: a–e:
2 μm; f–h: 500 nm; i–p: 100 μm; q–t: 50 μm
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However, an MRI scan on patient 6 at 10 months was normal
and patients 2 and 3 have not yet had a scan.
SLC25A22 deficiency has been considered to cause an early-
onset seizure disorder with no associated biochemical
Table 1 Clinical phenotype and
demographics of patients with
SCL25A22 mutations
Clinical features & demographics Incidence
Gender Male; 8/15 (53%)
Female; 7/15 (47%)
Country of origin Afghanistan; 3/15 (20%)
Syria; 2/15 (13%)
Israel; 6/15 (40%)
Algeria; 1/15 (7%)
Saudi Arabia; 2/15 (13%)
British/Finnish; 1/15 (7%)
Parental consanguinity 14/15 (93%)
Age at seizure onset First week; 6/15 (40%)
1 week – 1 month; 3/15 (20%)
1–3 months; 5/15 (33%)
7 years; 1/15 (7%)
Seizure type Neonatal/early infantile epileptic encephalopathy; 12/15 (80%)
Migrating partial seizures of infancy; 2/15 (13%)
Absence seizures in childhood; 1/15 (7%)
Response to AEDs None; 6/12 (50%)
Partial; 5/12 (42%)
Yes; 1/12 (8%)
Distinct EEG features Burst-suppression; 5/12 (42%)
Multifocal; 5/12 (42%)
Delta brush pattern; 1/12 (8%)
Irregular slow wave activity; 1/12 (8%)
VEP Abnormal; 5/8 (63%)
Normal; 3/8 (37%)
ERG Abnormal; 2/4 (50%)
Normal; 2/4 (50%)
Other ocular findings described No fixing/following; 2/13 (15%)
No response to light; 5/13 (38%)
Retinal pigmentation; 1/13 (8%)
Hypermetropia, astigmatism, convergent squint; 1/13 (8%)
Normal; 2/13 (15%)
Microcephaly 7/7 (100%)
MRI Hypoplastic corpus callosum/splenium; 8/11 (72%)
Cerebellar hypoplasia/prominent folia; 5/11 (45%)
Delayed myelination; 4/11 (36%)
Brain atrophy; 4/11 (36%)
Subarachnoid enlargement; 2/11 (18%)
White matter abnormalities; 2/11 (18%)
Frontotemporal hypoplasia; 1/11 (9%)
Normal; 1/11 (9%)
Biochemical findings Persistently elevated plasma proline; 3/6 (50%)
Intermittently elevated plasma proline; 1/6 (17%)
Intermittently elevated plasma ornithine or arginine; 5/6 (83%)
Vacuolated fibroblasts (mostly empty); 3/3 (100%)
AEDs antiepileptic drugs, ERG electroretinography, VEP visual evoked potential
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abnormalities. However, in this series, one patient was referred
with hyperprolinaemia and in another three it was detected on
first line investigations. The metabolic pathways for catabolism,
cycling and synthesis of proline are shown in Fig. 3. Proline
enters mitochondria from the cytosol and proline dehydrogenase
converts proline to pyrroline-5-carboxylate (P5C). In bacteria,
the reducing equivalents are transferred to ubiquinone to form
ubiquinol (Natarajan and Becker 2012). P5C can then be
transported out of the mitochondrion or further metabolised.
The P5C efflux transporter is unknown (Miller et al 2009).
However, cytosolic P5C can be converted back to proline by
P5C reductase using reducing equivalents from NADPH, thus
completing the proline/P5C shuttle, the net result of which is
transfer of reducing equivalents from cytosolic NADPH to the
mitochondrial respiratory chain.
Alternatively, P5C in mitochondria can undergo non-
enzymatic hydrolysis to generate glutamate-γ-semialdehyde
(GSA). GSA can be further metabolised to either glutamate or
ornithine and arginine. All the intramitochondrial metabolic
interconversions can influence plasma amino acid concentra-
tions, as exemplified by the abnormalities characteristic of
deficiencies of proline dehydrogenase, P5C dehydrogenase,
P5C synthase and orni th ine δ -aminot ransferase
(Baumgartner et al 2005).
Inmany cells, glutamate is synthesised from 2-oxoglutarate
produced in the Krebs cycle and the net flux of glutamate and
P5C is likely to be from mitochondrion to cytosol. In patients
with SLC25A22 deficiency, defective mitochondrial export of
glutamate or P5C could lead to high intramitochondrial con-
centrations and, as a consequence, reduced catabolism of pro-
line and increased synthesis of ornithine and arginine. We
suggest that the fact that 4/6 (67%) patients had persistently
or intermittently elevated plasma proline and 5/6 (83%) had
elevated plasma arginine and/or ornithine on at least one oc-
casion supports the hypothesis that export of glutamate and/or
P5C from the mitochondrion is disturbed. This hypothesis
requires that an important function of SLC25A22 is to trans-
port glutamate and/or GSA/P5C out of the mitochondria in
addition to acting as a glutamate importer. Bidirectional trans-
port of glutamate is supported by studies in liposomes
(Fiermonte et al 2002).
In liver cells the net flux of glutamate through the SLC25A22
transporter is probably from cytosol to mitochondria in the post
prandial period. Post-prandial plasma samples from patient 1
Fig. 2 Brain magnetic resonance
imaging of patients with
SLC25A22 deficiency. (a, d and
g) T2-weighted images. (b, c, f
and h) T1-weighted images. (e
and h) T1-weighted images with
inversion recovery sequence.
Patient 1 (2 y 1 m), patient 4 (6y
8 m) and patient 5 (2y 10 m). All
patients show frontotemporal
hypoplasia/atrophy (a, d and g)
and prominence of cerebellar
folia, consistent with cerebellar
hypoplasia/atrophy (b, e and h).
All patients also have a small
splenium, with the splenium of
the corpus callosum smaller than
the genu and a small optic
chiasma (smaller than the
mammillary body) (c, f and i).
Abnormal appearance of the
insular cortex is also noted in
patient 4 (d)
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showed elevated leucine, isoleucine, valine, alanine, tyrosine,
lysine and threonine (Supplementary Table 2 and Fig. 2); some
of these amino acidswere elevated in random samples fromother
patients. In the fed state, amino acids are the preferred fuel of the
liver. The influx from the portal vein leads to high concentrations
in the cytosol of hepatocytes. Leucine, isoleucine, valine, alanine
and tyrosine all undergo (reversible) transamination with 2-
oxoglutarate to produce glutamate and the glutamate needs to
be transported into the mitochondrion for deamination.
SLC25A22 likely fulfils this role. In the absence of
SLC25A22, high cytosolic levels of glutamate will impair trans-
amination and hence the plasma concentrations of the amino
acids are higher than normal in the post-prandial period. It is
possible that a standardised protein load will prove to be a better
marker of SLC25A22 deficiency than a random plasma proline
but further work will be needed to develop this.
Changes in glutamate concentration in mitochondria or in
the cytosol will be associated with corresponding changes in
2-oxoglutarate because of the presence of transaminases in
both sites. Changes in glutamate and 2-oxoglutarate can be
expected to affect the oxoglutarate/malate and aspartate/
glutamate transporters involved in the malate shuttle. These
could be reflected by abnormalities of plasma aspartate and of
urinary excretion of organic acids such as malate and 2-
oxoglutarate. However, the effects are likely to be opposite
in situations where the net flux through SLC25A22 is cytosol
> mitochondrion and mitochondrion > cytosol and these op-
posite effects may cancel one another out.
As indicated in Supplementary Table 3, plasma aspartate
levels were all normal except the one measured in patient 1 at
2 y 3 mo (32 μmol/L; ref 0–14). Interestingly this was also the
sample with the highest proline level. No obvious abnormalities
of organic acids were detected.
Patient 1 had a lowwhite cell ubiquinone. Disruption of the
proline/P5C shuttle may lead to reduced flux through proline
dehydrogenase. The electron acceptor for proline dehydroge-
nase in man is unknown, but in bacteria is ubiquinone
(Natarajan and Becker 2012). Perhaps a reduced proline flux
somehow leads to increased losses of ubiquinone.
Unfortunately, ubiquinone treatment of patients 2 and 3 did
not prevent the onset of seizures.
EM of fibroblasts demonstrated widespread vacuolation, with
Oil Red O and Sudan Black staining indicating the presence of
neutral lipids and phospholipids (Fig. 1). Lipid synthesis can be
driven by increased cytosolic NADPH and citrate. In both pro-
liferating and quiescent fibroblasts the pentose phosphate path-
way produces cytosolic NADPH (Lemons et al 2010).
Impairment of the proline/P5C shuttle could lead to increased
cytosolic NADPH/NADP+. Increased intra-mitochondrial gluta-
mate is likely to lead to excessive Krebs cycle anaplerosis (or
acetyl-CoA production via malic enzymes) and hence excess
mitochondrial citrate production leading to export of citrate for
lipogenesis. Furthermore, when quiescent fibroblasts are fed
[U-13C]-glutamine the label appears in [5x13C]-citrate indicating
some conversion as follows: glutamine > glutamate > 2-
oxoglutarate > citrate. Export of citrate and build-up of cytosolic
NADPH is one of the postulated mechanisms for cytosolic lipid
accumulation in respiratory chain disorders. Our hypothesis of
impairment of the proline/P5C shuttle in SLC25A22 deficiency
requires that the protein transports P5C or GSA out of the
Fig. 3 Metabolism of proline and
proposed additional transporter
function of SLC25A22. Pathway
showing the synthesis,
degradation and interconversions
of proline, P5C and related
compounds within the
mitochondria. 1, proline
dehydrogenase; 2, P5C reductase;
3, ornithine δ-aminotransferase;
4, P5C synthase; 5, P5C
dehydrogenase; 6, non-
enzymatic; KA, keto-acid; AA,
amino acid
392 J Inherit Metab Dis (2017) 40:385–394
mitochondrion. The transporter responsible for this function is
not known; SLC25A22 is a possible candidate given the similar-
ity of GSA to glutamate.
Although the vacuoles did not contain organelle debris, we
investigated whether SLC25A22 deficiency may be inducing
autophagy. Autophagy can be induced by changes in amino
acid levels (Dodson et al 2013). Staining for p62 did show an
increase in number and size of autophagosomes (Fig. 1), sta-
tistically significant in one patient (Fig. 1W).
Lipid-containing vacuoles are seen in some LSDs. Therefore,
WES data was scrutinised for variants in LSD genes and a ho-
mozygous rare variant in SMPD1 (p.Val113Met) was identified
in one family. Sphingomyelinase activity was below the refer-
ence range but above that of affected individuals. Since vacuola-
tion was similar in all patients and there was no histochemical
evidence of sphingomyelin accumulation, it was concluded that
this variant was not pathogenic. Thus, we conclude that none of
the patients have a second genetic defect leading to lipid
accumulation.
Patient 1 had a low CSF pyridoxal 5’-phosphate (PLP). In
hyperprolinaemia type II (HP2), accumulation of P5C leads to
inactivation of PLP. If, as we have proposed, levels of P5C are
high in the mitochondrion then PLP might be inactivated in this
site and perhaps, as in HP2, this inactivation may contribute to
seizures.
In conclusion, mutations in SLC25A22 cause developmental
delay with late-onset seizures as well as neonatal-onset seizures.
Biochemical abnormalities can include hyperprolinaemia, and
lipid accumulation, features that may be useful markers.
Increased cytosolic lipid synthesis could indicate increased cyto-
solic NADPH and this, alongside hyperprolinaemia, suggests
impairment of the proline/P5C shuttle. Thus, we hypothesise that
SLC25A22 may transport pyrroline-5-carboxylate/glutamate-γ-
semialdehyde as well as glutamate.
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